1''-Benzylspiro[chroman-2,4''-piperidine] | 81109-74-2

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 哌啶类
• 英文名称: 1''-Benzylspiro[chroman-2,4''-piperidine]
• 英文别名: 1'-benzylspiro[3,4-dihydrochromene-2,4'-piperidine]
• CAS: 81109-74-2
• 化学式: C₂₀H₂₃NO
• 分子量: 293.4
• InChiKey: CRKWADRIYCMTBU-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.2
• 重原子数：
  22
• 可旋转键数：
  2
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.4
• 拓扑面积：
  12.5
• 氢给体数：
  0
• 氢受体数：
  2

文献信息

• [EN] DUAL NAV1.2/5HT2A INHIBITORS FOR TREATING CNS DISORDERS<br/>[FR] INHIBITEURS DOUBLES DE NAV1.2/5HT2A POUR TRAITER DES TROUBLES DU SNC
  申请人：SUNOVION PHARMACEUTICALS INC

  公开号：WO2018026371A1

  公开（公告）日：2018-02-08

  Compounds of formula I: I are disclosed, as are pharmaceutical compositions containing such compounds. Methods of treating neurological or psychiatric disorders in a patient in need are also disclosed. Such disorders include depression, bipolar disorder, pain, schizophrenia, obsessive compulsive disorder, addiction, social disorder, attention deficit hyperactivity disorder, an anxiety disorder, autism, a cognitive impairment, or a neuropsychiatric symptom such as apathy, depression, anxiety, psychosis, aggression, agitation, impulse control disorders, and sleep disorders in neurological disorders such as Alzheimer's and Parkinson's diseases.

  公开了化学式I的化合物，以及含有这些化合物的药物组合物。还公开了治疗患有神经系统或精神障碍的患者的方法。这些障碍包括抑郁症、躁郁症、疼痛、精神分裂症、强迫症、成瘾、社交障碍、注意力缺陷多动障碍、焦虑障碍、自闭症、认知障碍，或神经精神症状，如冷漠、抑郁、焦虑、精神病、攻击性、激动、冲动控制障碍，以及在神经系统疾病如阿尔茨海默病和帕金森病中的睡眠障碍。
• Piperidine derivatives
  申请人：H. LUNDBECK A/S

  公开号：EP0518805A1

  公开（公告）日：1992-12-16

  Piperidine compounds having the general general Formula I wherein R¹ is a) a group consisting of alkyl, alkenyl, cycloalkyl, cycloalkenyl, phenyl, cycloalkylalkyl, cycloalkenylalkyl, phenylalkyl or diphenylalkyl linked to the piperidyl N-atom through an at least 2 membered spacer group or; b) a group having the general Formula II : wherein X is CHR¹⁰, O, S, SO, SO₂ or NR¹⁰, R¹⁰ being hydrogen, alkyl or alkenyl, an amino group, sulfonyl, optionally substituted phenyl or a hetero aromatic group; Y is CH, CH₂, NH, C=O or C=S; Ra - Rd are substituents; U is CH₂, O or S; Q¹ is a bond , alkylene or alkenylen and Q² alkylene having at least two C-atoms or alkenylene R² and R³ are hydrogen, or alkyl or they may together form an ethylene or propylene bridge; R⁴ to R⁷ are substituents; and i) Z¹ and Z² are linked together in which case: Z¹ is CH₂, O or S; Z² and Z³ are independently (CH₂)n, n being 0 or 1, O or S or Z¹ and Z² may together represent a group -CH=CH-; or when Z³ is (CH₂)n wherein n is 0, Z¹ and Z² may together represent a 3-membered divalent group; or ii) when R¹ is a group as defined in b) Z¹ and Z² may also be unlinked, in which case: Z¹ is substituent, Z² is hydrogen and Z³ is (CH₂)n wherein n is 0; show potent sigma receptor activity. Furthermore they show effect in animal models indicative of anxiolytic properties. Accordingly they are useful as medicines for the treatment of anxiety, psychosis, epilepsy, convulsion, movement disorders, motor disturbances, amnesia, cerebrovascular diseases, senile dementia of the Alzheimer type or Parkinson's disease.

  具有一般式I的哌啶化合物，其中R¹是a)由至少2个成员的间隔基团连接到哌啶N原子的烷基，烯基，环烷基，环烯基，苯基，环烷基烷基，环烯基烷基，苯基烷基或二苯基烷基的群；或b)具有一般式II的群：其中X是CHR¹⁰，O，S，SO，SO₂或NR¹⁰，R¹⁰为氢，烷基或烯基，氨基，磺酰基，可选取代的苯基或杂环芳基；Y是CH，CH₂，NH，C=O或C=S；Ra至Rd是取代基；U是CH₂，O或S；Q¹是键，烷基或烯基，Q²是至少有两个C原子的烷基或烯基，R²和R³是氢，或烷基，或它们可以一起形成乙烯或丙烯桥；R⁴到R⁷是取代基；i）Z¹和Z²连接在一起的情况下：Z¹是CH₂，O或S；Z²和Z³是独立的（CH₂）n，n为0或1，O或S，或Z¹和Z²可以一起表示一个组-CH=CH-；或者当Z³为（CH₂）n，其中n为0时，Z¹和Z²可以一起表示一个3成员双价基团；或ii）当R¹是b）中定义的群时，Z¹和Z²也可以未连接，在这种情况下：Z¹是取代基，Z²是氢，Z³是（CH₂）n，其中n为0；具有强大的sigma受体活性。此外，它们在动物模型中表现出具有抗焦虑特性的效果。因此，它们可用作治疗焦虑症，精神病，癫痫，惊厥，运动障碍，记忆障碍，脑血管疾病，阿尔茨海默病或帕金森病的药物。
• Piperidine derivatives having anxiolytic effect
  申请人：H. LUNDBECK A/S

  公开号：EP0853085A1

  公开（公告）日：1998-07-15

  Piperidine compounds having the general general Formula I wherein R1 is a group consisting of alkyl, alkenyl, cycloalkyl, cycloalkenyl, phenyl, cycloalkylalkyl, cycloalkenylalkyl, phenylalkyl or diphenylalkyl linked to the piperidyl N-atom through an at least 2 membered spacer group or; R2 and R3 are hydrogen, or alkyl or they may together form an ethylene or propylene bridge; R4 to R7 are substituents; and Z1 is CH2, O or S; Z2 and Z3 are independently (CH2)n, n being 0 or 1, O or S or Z1 and Z2 may together represent a group -CH=CH-; or when Z3 is (CH2)n wherein n is 0, Z1 and Z2 may together represent a 3-membered divalent group; show potent sigma receptor activity. Furthermore they show effect in animal models indicative of anxiolytic properties. Accordingly they are useful as medicines for the treatment of anxiety, psychosis, epilepsy, convulsion, movement disorders, motor disturbances, amnesia, cerebrovascular diseases, senile dementia of the Alzheimer type or Parkinson's disease.

  具有一般通式 I 的哌啶化合物 其中 R1 是 由烷基、烯基、环烷基、环烯基、苯基、环烷基烷基、环烯基烷基、苯基烷基或二苯基烷基组成的基团，通过至少2个成员的间隔基团与哌啶基N原子相连；或 R2 和 R3 是氢、烷基或可共同形成乙烯桥或丙烯桥；R4 至 R7 是取代基；以及 Z1 是 CH2、O 或 S；Z2 和 Z3 独立地是 (CH2)n（n 为 0 或 1）、O 或 S，或者 Z1 和 Z2 可共同代表一个基团 -CH=CH-；或者当 Z3 是 (CH2)n 时（其中 n 为 0），Z1 和 Z2 可共同代表一个三元二价基团； 显示出强大的 sigma 受体活性。此外，它们在动物模型中显示出抗焦虑特性。因此，它们可用作治疗焦虑症、精神病、癫痫、抽搐、运动障碍、运动失调、健忘症、脑血管疾病、阿尔茨海默型老年痴呆症或帕金森病的药物。
• Dual NAV1.2/5HT2a inhibitors for treating CNS disorders
  申请人：Sunovion Pharmaceuticals Inc.

  公开号：US11186564B2

  公开（公告）日：2021-11-30

  Compounds of formula I: are disclosed, as are pharmaceutical compositions containing such compounds. Methods of treating neurological or psychiatric disorders in a patient in need are also disclosed. Such disorders include depression, bipolar disorder, pain, schizophrenia, obsessive compulsive disorder, addiction, social disorder, attention deficit hyperactivity disorder, an anxiety disorder, autism, a cognitive impairment, or a neuropsychiatric symptom such as apathy, depression, anxiety, psychosis, aggression, agitation, impulse control disorders, and sleep disorders in neurological disorders such as Alzheimer's and Parkinson's diseases.

  式 I 的化合物： 以及含有此类化合物的药物组合物。还公开了治疗有需要的患者的神经或精神障碍的方法。此类疾病包括抑郁症、双相情感障碍、疼痛、精神分裂症、强迫症、成瘾症、社交障碍、注意力缺陷多动障碍、焦虑症、自闭症、认知障碍或神经精神症状，如冷漠、抑郁、焦虑、精神病、攻击性、激动、冲动控制障碍，以及神经系统疾病如阿尔茨海默病和帕金森病的睡眠障碍。
• PIPERIDINE DERIVATES HAVING ANXIOLYTIC EFFECT
  申请人：H. LUNDBECK A/S

  公开号：EP0593511B1

  公开（公告）日：1998-09-02